RB1: a Prototype Tumor Suppressor and an Enigma

Overview

Journal Genes Dev

Specialty Molecular Biology

Date 2016 Jul 13

PMID 27401552

Citations 237

Authors

Nicholas J Dyson

Affiliations

Soon will be listed here.

Abstract

The retinoblastoma susceptibility gene (RB1) was the first tumor suppressor gene to be molecularly defined. RB1 mutations occur in almost all familial and sporadic forms of retinoblastoma, and this gene is mutated at variable frequencies in a variety of other human cancers. Because of its early discovery, the recessive nature of RB1 mutations, and its frequency of inactivation, RB1 is often described as a prototype for the class of tumor suppressor genes. Its gene product (pRB) regulates transcription and is a negative regulator of cell proliferation. Although these general features are well established, a precise description of pRB's mechanism of action has remained elusive. Indeed, in many regards, pRB remains an enigma. This review summarizes some recent developments in pRB research and focuses on progress toward answers for the three fundamental questions that sit at the heart of the pRB literature: What does pRB do? How does the inactivation of RB change the cell? How can our knowledge of RB function be exploited to provide better treatment for cancer patients?

Citing Articles

Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.

Chen X, Luo T, Zhang W, Wang S, Zhu M, He H BMC Med Genomics. 2025; 18(1):50.

PMID: 40087669 DOI: 10.1186/s12920-025-02116-5.

TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network.

Jones T, Feng J, Luyties O, Cozzolino K, Sanford L, Rimel J Sci Adv. 2025; 11(9):eadr9660.

PMID: 40020069 PMC: 11870056. DOI: 10.1126/sciadv.adr9660.

Distinct outcomes from targeted perturbations of the multi-subunit SCF E3 ubiquitin ligase in blocking Trp53/Rb1-null prostate tumorigenesis.

Xue Y, Zhu L, Karan S, Locker J, Branch C, Zhang J Commun Biol. 2025; 8(1):278.

PMID: 39987265 PMC: 11846996. DOI: 10.1038/s42003-025-07662-3.

Human cytomegalovirus UL82 promotes cell cycle progression of colorectal cancer by upregulating AGR2.

Ren H, Wang B, Wang L, Shi Y, Li R, Jiang C Commun Biol. 2025; 8(1):251.

PMID: 39962326 PMC: 11833063. DOI: 10.1038/s42003-025-07674-z.

DEAD/H Box 5 (DDX5) Augments E2F1-Induced Cell Death Independent of the Tumor Suppressor p53.

Nakajima R, Zhou Y, Shirasawa M, Nishimura N, Zhao L, Fikriyanti M Int J Mol Sci. 2025; 25(24.

PMID: 39769018 PMC: 11675670. DOI: 10.3390/ijms252413251.

References

Zappia M, Frolov M . E2F function in muscle growth is necessary and sufficient for viability in Drosophila. Nat Commun. 2016; 7:10509. PMC: 4740182. DOI: 10.1038/ncomms10509. View

Heilmann A, Perera R, Ecker V, Nicolay B, Bardeesy N, Benes C . CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res. 2014; 74(14):3947-58. PMC: 4122288. DOI: 10.1158/0008-5472.CAN-13-2923. View

Binne U, Classon M, Dick F, Wei W, Rape M, Kaelin Jr W . Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol. 2006; 9(2):225-32. DOI: 10.1038/ncb1532. View

Sharma A, Comstock C, Knudsen E, Cao K, Hess-Wilson J, Morey L . Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res. 2007; 67(13):6192-203. PMC: 4133940. DOI: 10.1158/0008-5472.CAN-06-4424. View

Hinds P, Mittnacht S, Dulic V, Arnold A, Reed S, Weinberg R . Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell. 1992; 70(6):993-1006. DOI: 10.1016/0092-8674(92)90249-c. View

Calo E, Quintero-Estades J, Danielian P, Nedelcu S, Berman S, Lees J . Rb regulates fate choice and lineage commitment in vivo. Nature. 2010; 466(7310):1110-4. PMC: 2933655. DOI: 10.1038/nature09264. View

Leduc C, Claverie P, Eymin B, Col E, Khochbin S, Brambilla E . p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation. Oncogene. 2006; 25(30):4147-54. DOI: 10.1038/sj.onc.1209446. View

Ciavarra G, Zacksenhaus E . Rescue of myogenic defects in Rb-deficient cells by inhibition of autophagy or by hypoxia-induced glycolytic shift. J Cell Biol. 2010; 191(2):291-301. PMC: 2958467. DOI: 10.1083/jcb.201005067. View

Nicolay B, Danielian P, Kottakis F, Lapek Jr J, Sanidas I, Miles W . Proteomic analysis of pRb loss highlights a signature of decreased mitochondrial oxidative phosphorylation. Genes Dev. 2015; 29(17):1875-89. PMC: 4573859. DOI: 10.1101/gad.264127.115. View

10.

Harrington E, Bruce J, Harlow E, Dyson N . pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci U S A. 1998; 95(20):11945-50. PMC: 21745. DOI: 10.1073/pnas.95.20.11945. View

11.

Miyake S, Sellers W, Safran M, Li X, Zhao W, Grossman S . Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol Cell Biol. 2000; 20(23):8889-902. PMC: 86544. DOI: 10.1128/MCB.20.23.8889-8902.2000. View

12.

Knudsen E, Buckmaster C, Chen T, Feramisco J, Wang J . Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev. 1998; 12(15):2278-92. PMC: 317048. DOI: 10.1101/gad.12.15.2278. View

13.

Vaughn D, Hwang W, Lal P, Rosen M, Gallagher M, ODwyer P . Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer. 2014; 121(9):1463-8. DOI: 10.1002/cncr.29213. View

14.

Dick F, Rubin S . Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol. 2013; 14(5):297-306. PMC: 4754300. DOI: 10.1038/nrm3567. View

15.

Ciavarra G, Zacksenhaus E . Multiple pathways counteract cell death induced by RB1 loss: implications for cancer. Cell Cycle. 2011; 10(10):1533-9. DOI: 10.4161/cc.10.10.15520. View

16.

Liu H, Tang X, Srivastava A, Pecot T, Daniel P, Hemmelgarn B . Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles. Nat Cell Biol. 2015; 17(8):1036-48. PMC: 4526313. DOI: 10.1038/ncb3210. View

17.

Pritchard E, Stewart E, Zhu F, Bradley C, Griffiths L, Yang L . Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma. Pharm Res. 2014; 31(11):3060-72. PMC: 4213378. DOI: 10.1007/s11095-014-1399-y. View

18.

Yamasaki L, Bronson R, Williams B, Dyson N, Harlow E, Jacks T . Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice. Nat Genet. 1998; 18(4):360-4. DOI: 10.1038/ng0498-360. View

19.

McClelland S, Burrell R, Swanton C . Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle. 2009; 8(20):3262-6. DOI: 10.4161/cc.8.20.9690. View

20.

Benevolenskaya E, Frolov M . Emerging links between E2F control and mitochondrial function. Cancer Res. 2015; 75(4):619-23. PMC: 4332890. DOI: 10.1158/0008-5472.CAN-14-2173. View